YmAbs (YMAB): חובות להיוון בספרים

Y-mAbs Therapeutics (YMAB) price action on GURU.Markets reflects the impact of single-drug dependency risks and EU delays, with the current indicator standing at 0.04. The business relies on Danyelza sales, which ensures high margins and a stable cash flow. Additionally, Y-mAbs Therapeutics is collaborating with Memorial Sloan Kettering to develop new antibodies to combat pediatric tumors.

This indicator measures the ratio of total liabilities to the net book value of assets, allowing for a real-time assessment of financial leverage and default risk. By analyzing the debt-to-book capitalization ratio, investors confirm the stability of Y-mAbs Therapeutics (YMAB), whose capitalization is protected by exceptional FDA orphan drug patent rights that preclude competition from generics.